Biological Monitoring of Nano Sized Particles in the Airways of Asthmatic Children (EHF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01754948|
Recruitment Status : Unknown
Verified December 2012 by Tel-Aviv Sourasky Medical Center.
Recruitment status was: Recruiting
First Posted : December 21, 2012
Last Update Posted : December 21, 2012
Background Ambient airborne particulate material (PM) is defined according the aerodynamic diameter into coarse, fine, and ultrafine or "nano" sized particles ranging between 2.5-10 µm (coarse), <2.5 µm (fine), and <0.1 µm (nano(. Many studies have examined particle effect on respiratory health in children, mainly by environmental monitoring of coarse and fine particles. Biological assessment of individual exposure to nano sized particles in correlation to adverse health effect was not previously studied.
Hypothesis individual exposure to nano sized particles in children is associated with reduction in forced expiratory volume at one second.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Observational Model:||Ecologic or Community|
|Official Title:||Biological Monitoring of Nano Sized Particles in the Airways of Asthmatic Children|
|Study Start Date :||July 2012|
|Estimated Primary Completion Date :||June 2013|
|Estimated Study Completion Date :||June 2013|
- spirometry values [ Time Frame: 1 sec ]forced expiratory volume at one second
- methacholine and adenosine challenge test results [ Time Frame: 1 sec ]provocative concentration causing a 20% fall in forced expiratory volume at one second and provocative dose causing a 20% fall in forced expiratory volume at one second
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01754948
|Contact: Shira Benor, MDemail@example.com|
|Contact: Elizabeth Fireman, Phdfirstname.lastname@example.org|
|Tel Aviv Medical Center||Recruiting|
|Tel Aviv, Israel|
|Contact: Shira Benor, MD email@example.com|
|Principal Investigator: Shira Benor|
|Principal Investigator: Shira Benor, MD|
|Study Director:||Shira Benor, MD||Tel Aviv Medical Center|